Slide 1: Capital Raising Presentation
For personal use only Capital Raising Presentation January 2017
Slide 2: Disclaimer
Disclaimer For personal use only Some of the information in this presentation may refer to Dimerix Limited (“Dimerix” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all
Slide 3: Company at a glance
Company at a glance For personal use only Corporate Snapshot ASX Code: DXB Share Price (20 Jan): $.008 Market cap: $12m Cash (31 Dec 16): $1.01m Pending R&D Rebate $0.42m Shares on issue: 1,497m Performance Shares: 75m Options: 98.7m Capital Raising @ 0.6c: $1.5-2m Top Shareholders (%) % Mr Peter Me
Slide 4: The Dimerix Investment Thesis
The Dimerix Investment Thesis For personal use only • Dimerix’s strategy stems from its Receptor-HIT technology. It allows Dimerix to generate exciting new drug candidates through identification of GPCR heterodimers • Lead program, DMX-200, is in Phase 2 trial for Chronic Kidney Disease (CKD) • Prop
Slide 5: Dimerix lead program – Why kidneys?
Dimerix lead program – Why kidneys? For personal use only Chronic Kidney Disease (CKD) – the big opportunity • A global unmet medical need leading to kidney failure, cardiovascular disease and premature death • Estimated 26 million people in the US suffer from CKD, from multiple causes • Estimated U
Slide 6: DMX-200 Phase 2 (Part A) Interim Data
DMX-200 Phase 2 (Part A) Interim Data For personal use only • Recruiting for Part A of its Phase 2 Trial of DMX-200 in Chronic Kidney Disease completed in November 2016 • Interim data shows DMX-200 well tolerated with encouraging safety profile • Participants dose of propagermanium (a CCR2 antagonis
Slide 7: What does Clinical Success look like?
What does Clinical Success look like? For personal use only • Currently, there are no approved treatments for FSGS, the disease is debilitating and if not treated leads to kidney failure and ultimately the requirement for transplant or dialysis • Patients with unresolved high levels of proteinuria h
Slide 8: DMX-200 Intellectual Property
DMX-200 Intellectual Property For personal use only • Dimerix has a granted patent in the USA (9,314,450); and granted and pending applications in other major jurisdictions • The ‘450 patent covers the use of CCR2 antagonists in conjunction with, or sequential to, administration of angiotensin recep
Slide 9: What else is happening in the CKD space?
What else is happening in the CKD space? For personal use only • NASDAQ Listed: RTRX, Market cap : ~US$817 million • Phase 2 asset, sparsentan, for treating FSGS – a dual angiotensin endothelin receptor blocker • Patients removed from Standard of Care treatment 2 weeks prior to dosing • Top line pos
Slide 10: What else is happening in the CKD space?
What else is happening in the CKD space? For personal use only • NASDAQ Listed code: CCXI, Market Cap: ~US$380 million, Cash: ~US$170 million • Completed Phase 2 for CCX140 in diabetic nephropathy (an indication of CKD) • CCX140 is a CCR2 antagonist, it showed a 24% reduction in proteinuria on backg
Slide 11: Value proposition of discovery platforms
Value proposition of discovery platforms For personal use only • GPCR – G Protein-Coupled Receptor: A large and important family of drug targets • Dimerix’s proprietary Receptor-HIT discovery platform enables new discovery around GPCRs • Used under contract by pharma and biotech in their internal di
Slide 12: Further Information
For personal use only Further Information Kathy Harrison James Williams Corporate Advisors - Australia Chief Executive Officer Executive Chairman Westar Capital Ltd +61 419 359 149 +61 409 050 519 +61 8 6268 2688 kathy.harrison@dimerix.com james@dimerix.com info@westarcapital.com.au Dimerix Limited